AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12972984
Drug: Low-dose right
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose right unilateral electroconvulsive therapy (approximately 2.25 times seizure threshold)
Trial: 12972984
Drug: High-dose right
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose right unilateral electroconvulsive therapy (greater than 2.25 times seizure threshold)
Trial: 12972984
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral electroconvulsive therapy (both doses)
Trial: 10940089
Drug: Naratriptan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan (2.5 mg orally)
Trial: 10940089
Drug: Sumatriptan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (50 mg orally)
Trial: 9009937
Drug: S&G/block (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S&G/block (1% lidocaine bilateral GPN blocks)
Trial: 9009937
Drug: S&G (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S&G (2% viscous lidocaine swish and gargle)
Trial: 9009937
Drug: S&G/spray (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S&G/spray (2% viscous lidocaine swish and gargle + 10% lidocaine spray)
Trial: 7932402
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (ampicillin, gentamicin and clindamycin)
Trial: 30099402
Drug: Guideline-based physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based physiotherapy treatment (control)
Trial: 26632161
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) administration of eptifibatide
Trial: 26632161
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of eptifibatide
Trial: 11115156
Drug: Alitretinoin gel
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin gel (0.05% or 0.1% applied twice daily for the first 2 weeks and up to 4 times daily thereafter)
Trial: 11115156
Drug: Alitretinoin gel
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin gel
Trial: 9154995
Drug: Angiotensin-II (A-II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II (A-II) at pressor doses (8.44 ng/kg/min)
Trial: 9154995
Drug: Angiotensin-II (A-II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II (A-II) at subpressor doses (0.62 ng/kg/min)
Trial: 8425695
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA), 3 mg.kg‐1.day‐1
Trial: 30243294
Drug: Propofol/remifentanil-based total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/remifentanil-based total intravenous anesthesia (TIVA group)
Trial: 24445147
Drug: Capecitabine (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1)
Trial: 24445147
Drug: Capecitabine (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1) + Cisplatin (70 mg/m² intravenously on day 1)
Trial: 20691266
Drug: PfCS102 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfCS102 (30 μg, twice)
Trial: 11286039
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral sumatriptan
Trial: 8972000
Drug: Sak42D (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sak42D (15 mg each, double bolus, 30 min apart)
Trial: 8972000
Drug: rt‐PA (accelerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA (accelerated weight-adjusted, maximum of 100 mg over 90 min)
Trial: 1600703
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (0.3 U kg‐1, 0.6 U kg‐1, 0.8 U kg‐1)
Trial: 1600703
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (4 U)
Trial: 1600703
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (6 U)
Trial: 2861219
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg procaterol
Trial: 2861219
Drug: 0.10 mg
RxNorm normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg procaterol
Trial: 27437937
Drug: Spent over
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spent over $500 for drugs and alcohol in the past month
Trial: 19008171
Drug: Standard continuous
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard continuous oxygen therapy (maximal flow rate of 2 L/min)
Trial: 15705022
Drug: Cetylated fatty
RxNorm normalized name: Cetyl Alcohol
DrugBank: Cetyl alcohol (DB09494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetylated fatty acid (CFA) topical cream applied twice per day for 30 days
Trial: 15705022
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical cream
Trial: 10472228
Drug: Ropivacaine (285
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (285 mg)
Trial: 1867580
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral intake of fluids (water, tea or coffee with sugar) without limitation of quantity
Trial: 7052613
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor (TF) administered subcutaneously equivalent to 5 x 10^8 lymphocytes, given twice at one week intervals and then every four weeks thereafter.
Trial: 25200559
Drug: Roux-en-Y gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux-en-Y gastric bypass (RYGB) plus optimised clinical treatment (OCT)
Trial: 25200559
Drug: Optimised clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised clinical treatment (OCT) alone
Trial: 17725934
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of lorazepam (n=47)
Trial: 15185267
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy for bulimia nervosa
Trial: 2565346
Drug: L-dopa (small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (small repeated doses)
Trial: 2565346
Drug: L-dopa (small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (small repeated doses) + haloperidol 15 mg
Trial: 100866
Drug: i.v. TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. TRH infusion (0.66 mg/hour) for 3 hours
Trial: 16086715
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg
Trial: 26407587
Drug: Hypoglycemic night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic night (PG target of 2.7-2.8 mmol/L maintained for 15 min)
Trial: 26407587
Drug: Normoglycemic night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemic night (PG maintained at 5.0-7.0 mmol/L)
Trial: 23704674
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (irrespective of group)
Trial: 21802658
Drug: remifentanil (MOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (MOR agonist)
Trial: 17615281
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg three times a day for 24 hours)
Trial: 11936460
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine excretion (inland territory)
Trial: 11936460
Drug: Urinary iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary iodine excretion (sea level)
Trial: 11936460
Drug: Median urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median urinary iodine excretion (inland villages)
Trial: 11936460
Drug: Median urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median urinary iodine excretion (Crotone)
Trial: 11936460
Drug: Median urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median urinary iodine excretion (Reggio Calabria)
Trial: 7769501
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g purified fish oil once a day for 6 months
Trial: 28749254
Drug: Mixed training
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed training (two moderate and two high-intensity sessions weekly)
Trial: 27609854
Drug: INSD ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INSD ketamine (1 mg/kg)
Trial: 27609854
Drug: IN fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IN fentanyl (1.5 μg/kg)
Trial: 25917674
Drug: Rotavirus vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccine (Rotarix)
Trial: 25917674
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (Tootsweet)
Trial: 8558644
Drug: Adjuvant CMV
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CMV chemotherapy (cisplatin, methotrexate, vinblastine)
Trial: 8558644
Drug: CMV chemotherapy
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV chemotherapy for salvage after relapse
Trial: 1869388
Drug: Tobramycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (100 mg)
Trial: 7041150
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment with topical chemotherapy and hydrotherapy
Trial: 29396217
Drug: Water treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water treatment
Trial: 31242190
Drug: Combined water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined water treatment, sanitation, and handwashing (WSH)
Trial: 24480899
Drug: 7-day intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day intensive cognitive therapy for PTSD
Trial: 24480899
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of standard weekly cognitive therapy
Trial: 24480899
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of weekly emotion-focused supportive therapy
Trial: 21842157
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg d,l‐methamphetamine
Trial: 19679580
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine (loading 3 microg kg(‐1) h(‐1) for 10 min; maintenance 0.2 microg kg(‐1) h(‐1) for 60 min)
Trial: 19679580
Drug: Moderate-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose dexmedetomidine (loading 6 microg kg(‐1) h(‐1) for 10 min; maintenance 0.4 microg kg(‐1) h(‐1) for 60 min)
Trial: 19679580
Drug: Dexmedetomidine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (both doses)
Trial: 17430414
Drug: Patients' daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' daily ratings of mood and functional impairment
Trial: 17430414
Drug: Patients' daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' daily ratings of mood
Trial: 12167446
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg) plus dexamethasone (8 mg)
Trial: 10539742
Drug: Sitostanol powder
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitostanol powder (1 g)
Trial: 10539742
Drug: Sitostanol in
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitostanol in lecithin micelles (700 mg)
Trial: 10539742
Drug: Sitostanol in
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitostanol in lecithin micelles (300 mg)
Trial: 7424927
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg epinephrine hydrochloride
Trial: 7424927
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg epinephrine hydrochloride
Trial: 7424927
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg epinephrine hydrochloride
Trial: 7424927
Drug: Control (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.1 mg and 0.3 mg)
Trial: 31699052
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with TAP block (40 mL of 0.375% ropivacaine)
Trial: 30113724
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (80 mg)
Trial: 30113724
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (120 mg)
Trial: 30113724
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (180 mg)
Trial: 27352504
Drug: Moxa salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxa salt packets at Zhongwan (CV 12) combined with tropisetron hydrochloride (5 mg)
Trial: 27352504
Drug: Tropisetron hydrochloride
RxNorm normalized name: tropisetron hydrochloride
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron hydrochloride (5 mg)
Trial: 23237204
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy in addition to orthoses therapy and home orientations
Trial: 23237204
Drug: Orthoses therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthoses therapy and home orientations
Trial: 20302573
Drug: UVB-LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB-LED therapy (high-dose group)
Trial: 20302573
Drug: UVB-LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB-LED therapy (low-dose group)
Trial: 15345158
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg after induction and placebo at 12 h postoperatively
Trial: 15345158
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg after induction and 1.25 mg at 12 h postoperatively
Trial: 15345158
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg plus Metoclopramide 10 mg after induction and droperidol 1.25 mg at 12 h postoperatively
Trial: 11594643
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise programme (cycling for up to 30 minutes three times weekly for 24-36 sessions over 12 weeks)
Trial: 2819572
Drug: One-day diet
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day diet control and oral dulcolax
Trial: 811350
Drug: Abdominal radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal radiation therapy alone
Trial: 811350
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiation therapy and chlorambucil
Trial: 28404609
Drug: Active moxibustion
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active moxibustion plus placebo gel
Trial: 28404609
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium gel plus placebo moxibustion
Trial: 23703599
Drug: Intravenous prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prophylactic ramosetron 0.3mg (Control)
Trial: 19407454
Drug: Pardoprunox (0.3‐42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pardoprunox (0.3‐42 mg/day)
Trial: 19407454
Drug: Pardoprunox (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pardoprunox (up to 18 mg/day) with intermediate steps
Trial: 14625336
Drug: 8 days
RxNorm normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Trial: 14625336
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Trial: 14625336
Drug: 8 days
RxNorm normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 days of antibiotic therapy (among patients with recurrent infections)
Trial: 14625336
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of antibiotic therapy (among patients with recurrent infections)
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g) + 0 mg alpha-tocopheryl acetate (placebo)
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g) + 100 mg alpha-tocopheryl acetate
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g) + 200 mg alpha-tocopheryl acetate
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g) + 400 mg alpha-tocopheryl acetate
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g)
Trial: 8561059
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (15g) + alpha-tocopheryl acetate
Trial: 29680222
Drug: Vocal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal therapy associated with electromyographic biofeedback
Trial: 29680222
Drug: Traditional vocal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional vocal therapy (Placebo Group)
Trial: 25003264
Drug: 12.5% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5% maltodextrin plus 15 g of glutamine (glutamine group)
Trial: 11443472
Drug: Preincisional ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional ketamine 1 mg/kg IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Trial: 11443472
Drug: Preincisional saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional saline IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Trial: 8032178
Drug: Commercially used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially used antiglaucoma agents with nasolacrimal occlusion
Trial: 31784300
Drug: Teduglutide treatment
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide treatment for 24 weeks
Trial: 18833170
Drug: Movalis injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movalis injected into trigger points (3 injections + 15 mg tablets per day)
Trial: 18833170
Drug: Movalis intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movalis intramuscular injection (3 injections + 15 mg tablets per day)
Trial: 11049005
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac (25 mg)
Trial: 11049005
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac (50 mg)
Trial: 11049005
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac (all doses)
Trial: 9093544
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy breakfast (over 20% of recommended daily energy intake)
Trial: 9093544
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy breakfast (less than 10% of recommended daily energy intake)